drugset / Trial / NCT04850560
Sequential Low-dose Decitabine With PD-1/CD28 CD19 CAR-T in Relapsed or Refractory B-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of CD19 PD-1/CD28-CAR-T sequential low-dose decitabine in the treatment of relapse or refractory B cell lymphoma.
Timeline
- Start
- 2021-05-18
- Primary completion
- 2022-05-01
- Completion
- 2024-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19 PD-1/CD28 CAR-T | Cell therapy | — | — |
| Subject | Decitabine | Small molecule | — | — |
Indications
No indication recorded.